Galera Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	5.69	11	22.84	20.21	20.95
Research & Development	0.35	3.15	24.12	31.01	52.42
Operating Expenses	6.04	14.15	46.95	51.23	73.37
Operating Income	-6.04	-14.15	-46.95	-51.23	-73.37
Interest Expense	-	-	-11.41	-11.57	-7.19
Interest & Investment Income	0.25	0.55	1.6	0.51	0.03
Currency Exchange Gain (Loss)	-	-0.01	-0	-0	-0
Other Non Operating Income (Expenses)	0.29	0.45	-	-	-
EBT Excluding Unusual Items	-5.5	-13.15	-56.77	-62.29	-80.53
Merger & Restructuring Charges	-	-	-2.31	-	-
Impairment of Goodwill	-	-0.88	-	-	-
Gain (Loss) on Sale of Assets	3.5	-	-	-	-
Asset Writedown	-	-2.26	-	-	-
Legal Settlements	-	0.98	-	-	-
Other Unusual Items	151.05	-	-	-	-
Pretax Income	149.05	-19.16	-59.08	-62.29	-80.53
Income Tax Expense	-	-0.2	-	-0.07	-
Net Income	149.05	-18.96	-59.08	-62.22	-80.53
Preferred Dividends & Other Adjustments	85.53	-0.22	-	-	-
Net Income to Common	63.52	-18.73	-59.08	-62.22	-80.53
Shares Outstanding (Basic)	99	55	45	27	26
Shares Outstanding (Diluted)	99	55	45	27	26
Shares Change (YoY)	80.30%	22.63%	64.47%	5.03%	3.70%
EPS (Basic)	0.64	-0.34	-1.33	-2.30	-3.12
EPS (Diluted)	0.64	-0.34	-1.33	-2.30	-3.12
Free Cash Flow	-6.05	-12.15	-44.91	-43.45	-68.24
Free Cash Flow Per Share	-0.06	-0.22	-1.01	-1.60	-2.65
EBITDA	-6.02	-14.13	-46.69	-51.11	-72.59
D&A For EBITDA	0.02	0.02	0.26	0.11	0.78
EBIT	-6.04	-14.15	-46.95	-51.23	-73.37

Source: S&P Global Market Intelligence. Standard template. Financial Sources.